FUS and amyotrophic lateral sclerosis: It is thus notable that a growing body of evidence suggests that neurofilaments show promise as susceptibility/risk biomarkers given their potential to track disease progression and possibly predict the timing of clinical phenoconversion for asymptomatic individuals with a known mutation in an ALS-associated gene [e.g., superoxide dismutase 1 (SOD1), C9orf72-SMCR8 complex subunit (C9orf72), FUS RNA binding protein (FUS)] [7].